Myriad Genetic Laboratories, Inc. is excited to announce the addition of full sequencing analysis of a new gene, HOXB13, to the Myriad myRisk® Hereditary Cancer Panel, planned for October 11, 2018.
The G84E (c.251G>A) variant in the HOXB13 gene is associated with an increased risk of prostate cancer that is significantly higher than the general population risk for prostate cancer.123 This HOXB13 variant has also been linked to prostate cancer occurring at an earlier age.3
At this time, no other variants in HOXB13 have been linked to an increased risk of prostate cancer, but myRisk testing will include full sequencing of the gene in order to accommodate new information about additional HOXB13 variants that impact patient care.
Each gene tested with Myriad myRisk links to one or more of eight cancer sites: Breast, Ovarian, Colorectal, Endometrial, Melanoma, Pancreatic, Gastric, and Prostate.
Myriad myRisk simplifies the test selection process by providing you the most comprehensive hereditary cancer panel test with clinically significant results. Be confident you are testing for the primary clinically significant genes associated with your patients’ risk
Please check back periodically for more information as we prepare to add HOXB13 to the Myriad myRisk® Hereditary Cancer panel.
You may also reach out to your local Myriad Account Executive or Regional Medical Specialist, or call 1-800-4-MYRIAD (800-469-7423) for more information. For a full list of the genes currently included on Myriad myRisk, please view the Myriad myRisk® Gene Table.